News & Events

Publications

Elife: Antimicrobials from a Feline commensal bacterium inhibit skin infection by drug-resistant S. pseudintermedius [Read More]

Nature Medicine: Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial [Read More]

Cell Reports: Interplay of Staphylococcal and Host Proteases Promotes Skin Barrier Disruption in Netherton Syndrome [Read More]

Journal of Investigative Dermatology: Identification of a Human Skin Commensal Bacterium that Selectively Kills Cutibacterium acnes [Read More]

Science Translational Medicine: Quorum sensing between bacterial species on the skin protects against epidermal injury in atopic dermatitis [Read More]

Press Releases

MatriSys Bioscience Announces Corporate and Strategic Update January 04, 2023

MatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-resistant S. pseudintermedius October 21, 2021

MatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology Summit July 29, 2021

MatriSys Bioscience Names Joyce Rico as Chief Medical Officer March 25, 2021

MatriSys Bioscience Expands Licensing Agreement with UCSD School of Medicine to Develop Acne Treatment March 18, 2021

MatriSys Bioscience Raises more than $3 million to Advance its Portfolio of Products to Treat Inflammatory Skin Diseases March 11, 2021

Presentations

Biocom Global Life Science Partnering Conference

Tue, Feb 23, 2021 – Thu, Feb 25, 2021

4th Microbiome Movement Skin Health & Dermatology Summit

Tue, Aug 3, 2021 – Thu, Aug 5, 2021

Media

MedPage Today: Using the Skin Microbiome to Control Atopic Dermatitis [Read More]